ClinicalTrials.gg
RecruitingNCT07858422Updated Oct 5, 2026

A Study to Evaluate ENERGI-F703EB Cream in Epidermolysis Bullosa

A Phase 2 interventional study of ENERGI-F703EB Cream and Matched vehicle cream in Epidermolysis Bullosa (EB), Junctional Epidermolysis Bullosa and Epidermolysis Bullosa Simplex, sponsored by Energenesis Biomedical Co., Ltd.. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Energenesis Biomedical Co., Ltd. · Phase 2, Interventional, and Treatment

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a phase II, intra-subject randomized, double-blind, vehicle-controlled, parallel, multicenter study to evaluate the safety and preliminary efficacy of ENERGI-F703EB Cream in subjects who are ≥ 18 years old with epidermolysis bullosa simplex (EBS), junctional epidermolysis bullosa (JEB), or dystrophic epidermolysis bullosa (DEB). In total, approximately 24 subjects will be enrolled from multiple sites in Taiwan. The study duration per subject is approximately 16 weeks; which includes a 2 to 4-week period between Visit 1 and Visit 2 for screening, an 8-week period from Visit 2 to Visit 7 for treatment, and a 4-week period from Visit 7 to Visit 9 for safety follow-up.

02

Conditions studied

  • Epidermolysis Bullosa (EB)
  • Junctional Epidermolysis Bullosa
  • Epidermolysis Bullosa Simplex
  • Dystrophic Epidermolysis Bullosa

Keywords

  • Epidermolysis Bullosa
  • EB
03

In context

Epidermolysis Bullosa

86 studies on the registry are indexed under Epidermolysis Bullosa; 18 are open to participants now.

This study's planned enrollment of 24 is above the median of 15 across 68 interventional studies indexed under Epidermolysis Bullosa.

Browse Epidermolysis Bullosa studies →

Lead sponsor

Energenesis Biomedical Co., Ltd. is the lead sponsor of 7 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A subject is eligible for the study if all of the following apply:

  1. With either gender aged ≥ 18 years old at the Screening Visit.
  2. Subject has clinical diagnosis and laboratory evidence of EB simplex, junctional EB, or dystrophic EB.

    Note: Subjects may be included if diagnostic testing confirms subtype. Acceptable diagnostic testing methods include transmission electron microscopy and immunofluorescence studies.

  3. Potential target and target lesions can be located anywhere on the body except on or near the joints (e.g., the elbows and the ankle), face, scalp, groin, palms and soles.
  4. Potential target lesions have been present for ≥ 21 days and \< 9 months at the Screening Visit (Visit 1).
  5. Subject's target EB lesions in the matched target lesion pair fulfill all of the following criteria at the Baseline Visit (Visit 2):

    1. The size of each lesion is between 10 - 40 cm2.
    2. Each lesion did not exhibit ≥ 30% reduction in size compared to the measurement taken at the Screening Visit.
    3. The two lesions have a size difference of ≤ 20%.
    4. The two lesions are separated by ≥ 6 cm apart from each other.
  6. Subject is able and willing to follow study procedures and instructions.
  7. Subject has signed the written form.
  8. Male subjects must be surgically sterile or commit to the use of a highly effective method of (See Appendix 1) for the duration of the study.
  9. Female subjects are eligible only if all of the following apply:

    1. Not pregnant with a negative serum or urine pregnancy test at the Screening Visit and at Visit 2 before randomization (test not required for females of non-).
    2. Not lactating.
    3. Not planning to become pregnant during the study.
    4. If of childbearing potential, commits to the use of a highly effective method of contraception for the duration of the study (See Appendix 1 for acceptable methods of contraception).

Exclusion criteria

Exclusion Criteria:

A subject meeting any of the exclusion criteria will be excluded from study participation:

  1. Subject's target EB lesions in the matched target lesion pair fulfill any of the following criteria:

    1. Have clinical signs of infection as evidenced by ongoing adverse event and/or use of topical antibiotics within 14 days prior to Visit 2.
    2. Use of topical steroidal therapy within 28 days prior to Visit 2.
    3. Use of topical silver products (e.g. silver sulfadiazine cream, colloidal silver) within 14 days prior to Visit 2.
  2. Use of systemic steroidal therapy within 28 days prior to Visit 2 (Except for inhaled, ophthalmic, or for systemic manifestations of EB per investigator's discretion).
  3. Subject has a current or history of within 2 years prior to Visit 2.
  4. Use of any other drug within 28 days prior to the Screening Visit.
  5. With known or suspected to any ingredients in ENERGI-F703EB Cream or matched vehicle cream.
  6. With any of the following impaired hepatic or renal functions at the Screening Visit:

    1. or AST > 2×
    2. Total > 1.5× ULN
    3. \< 30 mL/min/1.73 m2

    Note: For eGFR, the CKD-EPI creatinine equation (2021) will be used: eGFR (mL/min/1.73 m2) = 142 × min (SCr/K, 1)α × max (SCr/K, 1)-1.200 × 0.9938age × (1.012 if female); where:

    • SCr = serum creatinine (mg/dL)
    • K = 0.7 (females) or 0.9 (males)
    • α = -0.241 (females) or -0.302 (males)
    • min = indicates minimum of SCr/K or 1
    • max = indicates maximum of SCr /K or 1
  7. With any condition judged by the investigator that entering the trial may be detrimental to the subject.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (estimated)

Study arms

  • Active comparator
    ENERGI-F703EB Cream

    Drug: ENERGI-F703EB Cream

  • Placebo comparator
    Matched vehicle cream

    Drug: Matched vehicle cream

Interventions

  • DrugENERGI-F703EB Cream

    Standard of care and ENERGI-F703EB Cream is applied for the treatment of Epidermolysis Bullosa

  • DrugMatched vehicle cream

    Standard of care and matched vehicle cream is applied for the treatment of Epidermolysis Bullosa

06

What researchers measure

Primary outcomes

  1. Incidence of Local Target Lesion Adverse Events

    Number of local target lesion adverse events with onset during the specified assessment period.

    Time frame: Day 1 through Day 85

Secondary outcomes

  1. Incidence of Adverse Events Excluding Local Target Lesion Adverse Events

    Number of adverse events, excluding local target lesion adverse events, with onset during the specified assessment period.

    Time frame: Day 1 through Day 85

  2. Number of participants with abnormalities in vital signs

    Vital signs measurement consist of systolic and diastolic blood pressure, respiratory rate, pulse rate, and body temperature.

    Time frame: Baseline to Days 15, 29, 43, 57, 71, and 85

  3. Number of participants with abnormalities in laboratory examination results

    Laboratory tests to be measured in this study will consist of the following: * Hematology: white blood cell (WBC), neutrophils, lymphocytes, monocytes, eosinophils, basophils, hemoglobin, hematocrit, platelets, red blood cells (RBC). * Biochemistry: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total bilirubin, direct bilirubin, glucose, HbA1c, serum creatinine, blood urea nitrogen (BUN), albumin, prealbumin, and estimated glomerular filtration rate (eGFR). * Urinalysis: chemical strip (specific gravity, pH, occult blood, leukocytes, glucose, protein, ketones, bilirubin.

    Time frame: Baseline to Days 57 and 85

  4. Number of Subjects With Abnormal Physical Examination Findings

    Number of subjects with abnormal physical examination findings at Day 57 and Day 85.

    Time frame: Day 57 and Day 85

  5. Proportion of Target Lesions With Complete Lesion Closure

    Proportion of target lesions with complete lesion closure as assessed by the investigator at each specified visit.

    Time frame: Days 15, 29, 43, and 57

  6. Intra-Subject Comparison of Target Lesion Re-epithelialization

    Intra-subject comparison of target lesions with respect to re-epithelialization as assessed by the investigator at each specified visit.

    Time frame: Days 15, 29, 43, and 57

  7. Net Change From Baseline in Target Lesion Size

    Net change in target lesion size from baseline at each specified visit.

    Time frame: Baseline to Days 15, 29, 43, and 57

  8. Percent Change From Baseline in Target Lesion Size

    Percent change in target lesion size from baseline at each specified visit.

    Time frame: Baseline to Days 15, 29, 43, and 57

  9. Time to First Target Lesion Closure

    Time from baseline to the first occurrence of target lesion closure.

    Time frame: Baseline through Day 57

  10. Proportion of Target Lesions With at Least 50% Lesion Closure

    Proportion of target lesions achieving at least 50% lesion closure at each specified visit.

    Time frame: Days 15, 29, 43, and 57

  11. Proportion of Target Lesions With at Least 75% Lesion Closure

    Proportion of target lesions achieving at least 75% lesion closure at each specified visit.

    Time frame: Days 15, 29, 43, and 57

  12. Proportion of Target Lesions With at Least One Complete Lesion Closure

    Proportion of target lesions that achieved complete lesion closure at least once, as assessed by the investigator, at any assessment up to Visit 7, regardless of subsequent reopening.

    Time frame: Baseline through Day 57

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Mar 2027, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2026
First posted
Oct 5, 2026
StartEst.
Oct 8, 2026
Primary completionEst.
Mar 15, 2027
CompletionEst.
Jun 15, 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07858422
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Oct 8, 2026 (estimated)
Primary completion
Mar 15, 2027 (estimated)
Completion
Jun 15, 2027 (estimated)
Last update
Oct 5, 2026

Study contacts

Yifang Cheng, PhD
Contact
ct@energenesis-biomedical.com
+886-2-26270835

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion